A
Advicenne
Biotech & Life Sciences · Paris, France · Founded 2007 · IPO 2017
Develops and markets pediatric drugs for the treatment of neurological diseases of the central nervous system and nephrological disorders MoreLess
Advicenne is a pharmaceutical company focused on developing and commercializing innovative treatments for rare renal diseases. The company serves both children and adults, addressing high unmet medical needs in the healthcare market. Advicenne operates primarily in Europe and the United States, with its headquarters in Paris. The company's business model revolves around the reformulation and delivery of groundbreaking medicines, leveraging its expertise to create products that improve daily health and life. Advicenne generates revenue through the sale of its approved medications, such as the combination of Potassium citrate and Potassium bicarbonate, which received approval from the European Medicine Agency and MHRA in 2021. Listed on Euronext Growth (Euronext ALDVI) since 2022, Advicenne continues to expand its portfolio and market reach. Keywords: rare renal diseases, innovative treatments, pharmaceutical, reformulation, drug delivery, children and adults, high unmet medical need, quality of life, European Medicine Agency, Euronext Growth.
Company overview
Advicenne company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2007
- Headquarters
- Paris, France
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 69.5
Valuation & funding
Advicenne funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2026 | $4.2M | — | Cemag Invest · L1 Capital | ↗ |
| POST IPO EQUITY✓Other financing | Jul 2025 | $2.9M | — | Friedland Gestion · Marker Wizards · Treecap · Maitice Gestion | ↗ |
| POST IPO DEBT✓Debt | Dec 2022 | $5.5M | — | European Investment Bank | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2021 | $10M | — | Undisclosed | — |
| POST IPO DEBT✓Debt | Aug 2020 | $8.3M | — | European Investment Bank | ↗ |
| IPO✓Exit | Dec 2017 | Undisclosed | — | ||
| GROWTH EQUITY VC✓Equity / VC | Mar 2017 | iXO Private Equity · IRDI Gestion | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Advicenne website traffic
Latest recorded traffic for Advicenne is 1.1K monthly website visits, up 0% over the last three months. Advicenne's team grew 0% over the past year.
Comparisons
Advicenne compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Advicenne's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on Advicenne's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Advicenne has talent and traffic
team presence
In the news
Latest news about Advicenne
Recent press, funding announcements, and product moves mentioning Advicenne — open to read from the original sources.
Market sentiment
What the market is saying about Advicenne
An AI-synthesized read of the highest-engagement posts about Advicenne on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advicenne’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.